Generate Investment Management Ltd Acquires 8,720 Shares of Agilent Technologies, Inc. $A

Key Points

• Generate Investment Management Ltd. increased its Agilent Technologies stake by 10.8% in the third quarter, purchasing 8,720 additional shares for a total holding of 89,766 shares valued at approximately $15.5 million.
• Agilent reported quarterly earnings of $1.62 per share, beating estimates of $1.49, while revenue rose 8.1% year over year to $1.88 billion. The company also issued fiscal 2026 EPS guidance of $6.18 to $6.21.
• Analyst sentiment remains positive, with multiple firms raising price targets and the stock carrying a consensus “Moderate Buy” rating. Agilent also announced a quarterly dividend of $0.255 per share, representing a 0.6% annualized yield.

Generate Investment Management Ltd increased its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 10.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 89,766 shares of the medical research company's stock after purchasing an additional 8,720 shares during the period. Generate Investment Management Ltd's holdings in Agilent Technologies were worth $15,468,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp grew its holdings in Agilent Technologies by 0.7% in the 2nd quarter. State Street Corp now owns 12,854,230 shares of the medical research company's stock valued at $1,710,658,000 after buying an additional 89,598 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Agilent Technologies by 2.7% during the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company's stock worth $990,206,000 after buying an additional 198,253 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Agilent Technologies by 17.1% during the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company's stock worth $930,957,000 after buying an additional 1,024,516 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company's stock valued at $695,227,000 after acquiring an additional 2,440,360 shares during the period. Finally, Legal & General Group Plc bought a new stake in shares of Agilent Technologies in the second quarter valued at approximately $260,101,000.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $151.38, for a total value of $95,974.92. Following the sale, the director owned 4,924 shares of the company's stock, valued at $745,395.12. The trade was a 11.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Agilent Technologies Stock Performance

Agilent Technologies stock traded up $0.91 during trading hours on Wednesday, hitting $172.51. The stock had a trading volume of 659,733 shares, compared to its average volume of 2,258,416. The company has a 50-day moving average of $157.13 and a two-hundred day moving average of $136.41. The company has a quick ratio of 1.56, a current ratio of 2.05 and a debt-to-equity ratio of 0.50. Agilent Technologies, Inc. has a fifty-two week low of $108.35 and a fifty-two week high of $177.05. The company has a market cap of $48.64 billion, a PE ratio of 33.96, a price-to-earnings-growth ratio of 2.61 and a beta of 1.21.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.13. The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%. Agilent Technologies's revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, equities research analysts anticipate that Agilent Technologies, Inc. will post 6.20 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 28th. Shareholders of record on Tuesday, October 6th will be paid a dividend of $0.2550 per share. The ex-dividend date is Tuesday, October 6th. This represents a $1.02 dividend on an annualized basis and a yield of 0.6%. Agilent Technologies's payout ratio is currently 20.08%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on A. JPMorgan Chase & Co. boosted their target price on shares of Agilent Technologies from $180.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. Barclays upped their target price on shares of Agilent Technologies from $175.00 to $195.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Citigroup increased their price target on shares of Agilent Technologies from $185.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, August 27th. Morgan Stanley raised their price target on shares of Agilent Technologies from $175.00 to $190.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Stifel Nicolaus raised their price target on shares of Agilent Technologies from $170.00 to $180.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $173.65.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Proscia acquisition expands AI strategy: Agilent agreed to acquire digital pathology software company Proscia for $240 million upfront, with the transaction potentially reaching $270 million including milestone payments. The deal is intended to strengthen Agilent’s AI-enabled digital pathology and scientific intelligence capabilities, adding a strategic growth platform in clinical and research markets. Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
• Positive Sentiment: Analysts raised price targets: Morgan Stanley lifted its target from $175 to $190 and maintained an overweight rating, while TD Cowen raised its target from $180 to $196 and upgraded or maintained a buy rating. The revisions suggest analysts see additional upside following Agilent’s recent earnings outperformance and growth initiatives. TD Cowen Adjusts Price Target on Agilent Technologies to $196 From $180
• Positive Sentiment: Metabolomics market provides a growth tailwind: A new industry report projects a 17.3% compound annual growth rate through 2030, citing rising adoption of AI diagnostics and continued activity from Agilent, Thermo Fisher, Bruker and Metabolon. The outlook supports demand for Agilent’s analytical and life-science technologies. Global Metabolomics Market Report 2026
• Neutral Sentiment: China expansion: Agilent plans to expand its capabilities in China, potentially improving local customer support and strengthening its position in a major life-science market. However, China-related demand, trade conditions and regulatory risks remain considerations for investors. Agilent to expand capabilities in China

Agilent Technologies Company Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company's products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.